Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sofosbuvir/velpatasvir (Epclusa) for hepatitis C.

The Medical letter on drugs and therapeutics - 15 Aug 2016

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Drug Combinations
Share to Drug Interactions
Share to Hepatitis C
Share to Heterocyclic Compounds, 4 or More Rings

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protease Inhibitors

Share to Sofosbuvir

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 27508349

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sofosbuvir/velpatasvir (Epclusa) for hepatitis C.PMID 27508349Read ↗

Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C.Semantic proximity Read ↗

Sofosbuvir and Velpatasvir: A complete pan-genotypic treatment for HCV patients.Semantic proximity Read ↗

Sofosbuvir and velpatasvir for the treatment of hepatitis C.Semantic proximity Read ↗

Sofosbuvir for the treatment of hepatitis C virus infection.Semantic proximity Read ↗

Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.Semantic proximity Read ↗

A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.Semantic proximity Read ↗

Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes.Semantic proximity Read ↗

Effectiveness of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and virologic failure to direct-acting antivirals.Semantic proximity Read ↗

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure.Semantic proximity Read ↗

Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.Semantic proximity Read ↗

Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C.Semantic proximity Read ↗

Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.